Compare Cytokinetics Inc (CYTK) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Riot Platforms Inc — how do they compare? Cytokinetics Inc trades at $62.89 (market cap $8.62B), while Riot Platforms Inc trades at $16.9 (market cap $6.32B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Riot Platforms Inc is more actively traded (30,571,756 versus 2,594,626). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Riot Platforms Inc for 16 Days on average.
| CYTK | RIOT | |
|---|---|---|
Market Cap | $8.62B | $6.32B |
Volume | 2,594,626 | 30,571,756 |
Sector | Health | Financials |
52-Week High | $87.26 | $28.67 |
52-Week Low | $54.76 | $11.83 |
Typical Hold Time | 19 Days | 16 Days |
Enterprise Value | $8.72B | $6.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
RIOT stock trades at $16.95, down 8.58% over 24 hours, reflecting bearish technical signals despite a bullish analyst consensus. The company reported a net loss of $663.18 million in 2025, with negative profit margins and cash flow, but is pivoting to AI data center leasing with $9.8 billion in contracted revenue through 2048, per Seeking Alpha on 2026-10-01.
The outlook hinges on execution of the AI strategy, offering significant upside to the $31.64 consensus price target, but high execution risk and persistent losses pose threats to near-term shareholder value amid volatile market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
